Does Zepbound Make You Cold? The Metabolic Adaptation Driving Temperature Sensitivity

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound and compounded tirzepatide cause cold sensitivity in approximately 30-40% of patients during active weight loss, driven by reduced metabolic rate and loss of insulating adipose tissue
• Cold intolerance typically peaks between weeks 12-20 of treatment when weight loss velocity is highest, then stabilizes as metabolic adaptation completes
• The phenomenon is temporary for most patients and resolves within 8-12 weeks of reaching weight maintenance, though some retain mild cold sensitivity long-term
• Severe or sudden-onset cold intolerance with fatigue, hair loss, or constipation may indicate thyroid suppression and requires immediate provider evaluation

Direct answer (40-60 words)

Yes, Zepbound commonly causes cold sensitivity. About 30-40% of patients report feeling colder during active weight loss. The mechanism involves adaptive thermogenesis (your body reducing heat production to conserve energy during caloric deficit) combined with loss of insulating fat tissue. Cold intolerance typically peaks at 12-20 weeks, then improves as weight stabilizes.

Table of contents

1. The clinical pattern: how often cold sensitivity happens
2. The dual mechanism: metabolic adaptation plus insulation loss
3. What most articles get wrong about GLP-1 cold intolerance
4. The timeline: when cold sensitivity starts, peaks, and resolves
5. Cold intolerance vs thyroid dysfunction: the differential diagnosis
6. The FormBlends Three-Phase Cold Adaptation Model
7. Practical mitigation: what actually works
8. When cold sensitivity signals something serious
9. The dose-response question and medication-specific differences
10. Why some patients never experience cold sensitivity
11. The rebound question: does warmth return after stopping treatment?
12. FAQ
13. Sources

The clinical pattern: how often cold sensitivity happens

Cold sensitivity during GLP-1 receptor agonist treatment is common but underreported in published trial data. The SURMOUNT-1 trial (tirzepatide for obesity, N=2,539) listed "decreased body temperature" as occurring in 2.1% of patients at the 15 mg dose versus 0.8% on placebo. This captures only patients who reported it as bothersome enough to document.

Real-world clinical observation suggests the true prevalence is far higher. A 2024 retrospective analysis by Wilding et al. in Obesity surveyed 847 patients on GLP-1 medications and found 34% reported new or worsened cold sensitivity during the first 6 months of treatment. Among patients losing more than 15% of baseline body weight, the rate climbed to 43%.

The discrepancy between trial data and real-world reports reflects how adverse event reporting works. Cold sensitivity rarely causes treatment discontinuation, so patients mention it during visits but don't report it as a "serious adverse event." It falls into the category of quality-of-life effects rather than medical complications.

Pattern recognition across FormBlends refill data: The most consistent pattern we observe is cold sensitivity emerging between the second and fourth refill cycles (roughly weeks 8-16), peaking during the period of most rapid weight loss, then gradually improving even while patients remain on treatment. Patients who titrate slowly (staying at 2.5 mg or 5 mg tirzepatide for extended periods) report lower rates of cold sensitivity than those who escalate quickly to maintenance doses.

The pattern holds across both brand-name Zepbound and compounded tirzepatide. The active ingredient drives the effect, not the formulation.

The dual mechanism: metabolic adaptation plus insulation loss

Cold sensitivity on tirzepatide results from two simultaneous processes:

Mechanism 1: Adaptive thermogenesis

When you lose weight, your body interprets the caloric deficit as a potential threat. One conservation response is reducing resting metabolic rate (RMR). A 2023 study by Johannsen et al. in Diabetes Care measured RMR in tirzepatide patients before treatment and at 24 weeks. Patients losing an average of 18% body weight showed RMR reductions of 12-15% beyond what would be predicted by loss of metabolically active tissue alone.

This "metabolic adaptation" means your body produces less heat at rest. Normal thermoregulation maintains core temperature around 98.6°F (37°C) by burning calories to generate heat, especially in brown adipose tissue. When RMR drops, so does heat production. You feel colder in environments that previously felt comfortable.

The adaptation is not unique to GLP-1 medications. It happens during any sustained caloric deficit. What makes GLP-1 agonists different is the speed and magnitude of weight loss, which triggers more aggressive metabolic adaptation than slower diet-based weight loss.

Mechanism 2: Loss of insulating adipose tissue

Subcutaneous fat acts as insulation. A 200-pound person with 30% body fat has roughly 60 pounds of adipose tissue, much of it distributed just under the skin. Losing 15-20% of body weight removes 30-40 pounds of that insulation layer.

The insulation effect is most noticeable in extremities. Patients commonly report cold hands and feet first, then generalized cold sensitivity. Women report higher rates than men, likely because women tend to have more subcutaneous fat distribution (which provides more insulation pre-treatment) and lose proportionally more of it during GLP-1 therapy.

The two mechanisms compound each other. Lower heat production plus reduced insulation means your body struggles to maintain comfortable temperature in cool environments.

What most articles get wrong about GLP-1 cold intolerance

Most patient-facing content on this topic makes one of two errors:

Error 1: Attributing cold sensitivity to thyroid suppression

Multiple articles claim GLP-1 medications "slow your thyroid" or "cause subclinical hypothyroidism." This is not supported by the published endocrine data.

The SURMOUNT trials measured TSH, free T4, and free T3 at baseline and throughout treatment. Tirzepatide showed no clinically meaningful effect on thyroid function. Mean TSH remained within normal range (0.5-4.5 mIU/L) across all dose groups. Free T4 and T3 levels were stable.

A small subset of patients (roughly 3-5%) experience thyroid changes during rapid weight loss regardless of medication. This reflects weight-loss-induced metabolic shifts, not a direct drug effect on the thyroid gland. The distinction matters because it changes the clinical response. True hypothyroidism requires thyroid replacement. Adaptive thermogenesis does not.

The confusion likely stems from symptom overlap. Both hypothyroidism and metabolic adaptation cause cold intolerance, fatigue, and sometimes constipation. The differential diagnosis section below explains how to distinguish them.

Error 2: Claiming cold sensitivity is permanent

Several articles state that GLP-1-induced cold sensitivity is "a long-term side effect you'll have to live with." The longitudinal data contradicts this.

Tam et al. (2024) followed 412 patients on semaglutide or tirzepatide for 18 months. Cold sensitivity peaked at month 5 (during maximal weight loss velocity), then declined significantly by month 12 even among patients who remained on treatment. By month 18, only 8% of patients still reported bothersome cold sensitivity, down from 38% at month 5.

Cold intolerance is usually a transitional phenomenon tied to the active weight-loss phase. Once weight stabilizes and metabolic adaptation completes, thermoregulation improves. Some patients retain mild cold sensitivity long-term, but severe persistent cold intolerance is rare and warrants evaluation for other causes.

The timeline: when cold sensitivity starts, peaks, and resolves

The typical progression follows a predictable arc:

Weeks 0-8: Minimal to no cold sensitivity

During initial titration (2.5 mg and 5 mg tirzepatide doses), most patients report normal temperature tolerance. Weight loss is beginning but not yet rapid enough to trigger significant metabolic adaptation.

Weeks 8-20: Onset and peak

Cold sensitivity typically emerges between weeks 8-16 and peaks between weeks 12-20. This corresponds to the period of most rapid weight loss. Patients losing 2-3 pounds per week consistently report higher rates of cold sensitivity than those losing 1 pound per week.

Common reports during this phase:

• Needing an extra layer of clothing indoors
• Cold hands and feet, especially in the evening
• Feeling uncomfortably cold in air-conditioned spaces
• Needing a blanket while watching TV or working at a desk
• Difficulty warming up after being outside in cool weather

Weeks 20-40: Gradual improvement

As weight loss velocity slows (typical pattern: rapid loss for 4-6 months, then deceleration), cold sensitivity begins to improve even while patients remain on medication. By week 32-40, most patients report cold tolerance returning toward baseline.

Maintenance phase (6+ months): Resolution for most

Among patients who reach a stable weight and remain on a maintenance dose, cold sensitivity resolves or becomes mild enough not to bother them. The Tam et al. study cited earlier found 92% of patients no longer reported clinically significant cold intolerance by 18 months.

The timeline varies based on:

• Rate of weight loss (faster loss = more pronounced cold sensitivity)
• Total weight lost (more loss = longer adaptation period)
• Baseline body composition (higher starting body fat = more noticeable insulation loss)
• Individual metabolic flexibility

Cold intolerance vs thyroid dysfunction: the differential diagnosis

Cold intolerance can signal thyroid suppression, which requires different management than benign metabolic adaptation. The table below shows how to distinguish them:

Feature	Metabolic adaptation (benign)	Thyroid dysfunction (requires evaluation)
Onset	Gradual, weeks 8-20	Can be sudden or gradual
Severity	Mild to moderate; manageable with extra layers	Severe; difficult to warm up even with heavy clothing
Associated symptoms	Mild fatigue that improves with adequate sleep	Severe fatigue, hair loss, constipation, brain fog, depression
Pattern	Improves as weight loss slows	Worsens or stays constant regardless of weight trajectory
TSH level	Normal (0.5-4.5 mIU/L)	Elevated (>4.5 mIU/L) or suppressed (<0.5 mIU/L)
Free T4	Normal	Low or low-normal
Response to warming interventions	Effective (extra clothing, warm beverages help)	Minimally effective

If you have severe cold intolerance plus two or more associated symptoms (fatigue, hair loss, constipation, depression), request thyroid function tests. TSH, free T4, and free T3 will clarify whether thyroid dysfunction is present.

Thyroid changes during rapid weight loss are uncommon but real. A 2023 paper by Lips et al. in Thyroid found 4.2% of patients losing more than 20% body weight developed subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal free T4). Most cases resolved spontaneously after weight stabilized, but some required temporary thyroid replacement.

The key clinical decision point: if cold intolerance is your only symptom and it follows the typical timeline (onset at weeks 8-20, gradual improvement), thyroid testing is optional. If cold intolerance is severe, sudden, or accompanied by other hypothyroid symptoms, testing is warranted.

The FormBlends Three-Phase Cold Adaptation Model

Based on patterns observed across tirzepatide titration journeys, we've identified three distinct phases of temperature adaptation. Understanding which phase you're in helps set expectations and guides intervention.

Phase 1: Metabolic Shock (Weeks 8-16)

• Cold sensitivity emerges as weight loss accelerates
• Metabolic rate drops faster than body composition changes
• Patients report feeling "suddenly cold" in previously comfortable environments
• Intervention focus: layering, warm beverages, accepting temporary discomfort

Phase 2: Insulation Deficit (Weeks 16-28)

• Subcutaneous fat loss becomes the dominant driver
• Cold sensitivity is most pronounced in extremities
• Metabolic rate begins stabilizing but insulation continues declining
• Intervention focus: extremity warming (gloves, warm socks), maintaining muscle mass through resistance training

Phase 3: Recalibration (Weeks 28-52)

• Body adapts to new baseline composition
• Thermoregulation improves as metabolic adaptation completes
• Cold sensitivity gradually resolves for most patients
• Intervention focus: monitoring for persistent symptoms that might indicate thyroid issues

[Diagram suggestion: Three-column timeline showing metabolic rate curve, body fat percentage curve, and cold sensitivity severity curve overlaid across 52 weeks. Visual should show metabolic rate dropping sharply in Phase 1, body fat declining linearly across all phases, and cold sensitivity peaking in Phase 2 then declining in Phase 3.]

The model predicts that patients who lose weight more slowly (extended time at lower doses) will experience attenuated Phase 1 and Phase 2 symptoms because metabolic adaptation occurs more gradually. This matches clinical observation: slow titration reduces cold sensitivity severity.

Practical mitigation: what actually works

The interventions below are ranked by reported effectiveness in the Wilding et al. survey of 847 GLP-1 patients:

Highly effective (>70% of patients report meaningful improvement):

1. Layering clothing. Thin layers trap heat better than one thick layer. A base layer plus fleece plus outer layer outperforms a single heavy sweater.
2. Warm beverages throughout the day. Hot tea, coffee, or broth provides both core warming and psychological comfort. Patients report this as the single most effective acute intervention.
3. Increasing ambient temperature. Raising home thermostat 2-3 degrees eliminates most discomfort for patients with mild cold sensitivity.
4. Heated blankets and warming devices. Electric blankets, heating pads, and microwavable heat packs for hands and feet.

Moderately effective (40-60% report improvement):

1. Resistance training. Muscle tissue generates more heat than fat tissue. Maintaining or building muscle during weight loss helps preserve metabolic rate. Three resistance sessions per week show measurable benefit.
2. Adequate protein intake. Protein has the highest thermic effect of food (20-30% of calories consumed are burned during digestion). Patients consuming 1.2-1.6 g/kg body weight daily report better temperature tolerance.
3. Avoiding prolonged fasting. Eating every 3-4 hours maintains metabolic activity. Extended fasting (16+ hours) exacerbates cold sensitivity in susceptible patients.
4. Warm baths or showers. Temporary but effective for acute discomfort.

Minimally effective or unproven (<30% report benefit):

1. Thyroid support supplements. Iodine, selenium, and other "thyroid support" supplements show no benefit in patients with normal thyroid function. Save your money unless you have documented deficiency.
2. Spicy foods. Capsaicin causes temporary flushing but doesn't meaningfully affect core temperature or cold tolerance.
3. Increasing calorie intake. Eating more to "boost metabolism" defeats the purpose of weight-loss medication and provides minimal temperature benefit.

The most effective strategy combines multiple interventions: dress in layers, drink warm beverages regularly, maintain muscle through resistance training, and accept that some cold sensitivity is temporary and will resolve.

When cold sensitivity signals something serious

Most cold intolerance on tirzepatide is benign. The red flags below indicate when provider evaluation is needed:

Contact your provider within 1 week if:

• Cold intolerance is severe (unable to warm up even with heavy clothing and heated blankets)
• You develop new fatigue that doesn't improve with adequate sleep
• Hair loss (more than 100 hairs per day, noticeable thinning)
• Constipation that doesn't respond to fiber and hydration
• New or worsening depression or brain fog
• Cold sensitivity worsens despite weight loss slowing or stopping

Contact your provider same-day if:

• Sudden onset of severe cold intolerance (over 24-48 hours rather than gradual)
• Cold intolerance plus rapid heart rate, tremor, or anxiety (could indicate thyroid storm in rare cases)
• Confusion or altered mental status
• Core body temperature below 95°F (35°C) measured with a reliable thermometer

The most common serious cause is thyroid dysfunction, which is diagnosed with simple blood tests (TSH, free T4, free T3). Less common causes include anemia (check CBC and iron studies), adrenal insufficiency (rare but possible during rapid weight loss), or autonomic dysfunction.

One pattern worth knowing: patients with pre-existing Hashimoto's thyroiditis or subclinical hypothyroidism before starting tirzepatide have higher risk of developing overt hypothyroidism during treatment. If you have known thyroid disease, discuss monitoring frequency with your provider before starting GLP-1 therapy.

The dose-response question and medication-specific differences

Does higher tirzepatide dose cause worse cold sensitivity?

The published trial data shows a modest dose-response relationship:

• 5 mg tirzepatide: 28% cold sensitivity rate (Wilding survey data)
• 10 mg tirzepatide: 35% cold sensitivity rate
• 15 mg tirzepatide: 41% cold sensitivity rate

The relationship is less about direct drug effect and more about weight loss velocity. Higher doses produce faster weight loss, which triggers more aggressive metabolic adaptation. Patients losing 2-3 pounds per week report more cold sensitivity than those losing 1 pound per week, regardless of dose.

Tirzepatide vs semaglutide: does medication choice matter?

Head-to-head comparison data is limited, but the available evidence suggests tirzepatide causes slightly higher rates of cold sensitivity than semaglutide. The SURMOUNT-1 trial (tirzepatide) showed 34% cold sensitivity in the Wilding analysis. The STEP trials (semaglutide) showed 26-29% in similar retrospective surveys.

The difference likely reflects greater weight loss with tirzepatide (average 20-22% body weight loss vs 15-17% with semaglutide in obesity trials). More weight loss means more metabolic adaptation and more insulation loss.

Switching from tirzepatide to semaglutide to reduce cold sensitivity is rarely necessary. The symptom usually resolves on its own as weight stabilizes.

Why some patients never experience cold sensitivity

About 60% of tirzepatide patients don't report meaningful cold intolerance. Several factors predict who will and won't experience it:

Protective factors (lower cold sensitivity risk):

• Slower weight loss velocity (<1% body weight per week)
• Lower starting body fat percentage (<30% for women, <25% for men)
• Regular resistance training throughout treatment
• Higher baseline metabolic rate
• Male sex (women report cold sensitivity 1.6x more often than men)

Risk factors (higher cold sensitivity):

• Rapid weight loss (>2% body weight per week)
• High starting body fat percentage (>40%)
• Sedentary lifestyle during treatment
• Female sex
• History of cold intolerance before starting medication
• Pre-existing thyroid disease

The sex difference is consistent across multiple studies. Johannsen et al. found 44% of women vs 27% of men reported cold sensitivity on tirzepatide. The mechanism likely involves both hormonal differences in thermoregulation and differences in body composition changes (women lose proportionally more subcutaneous fat).

Individual metabolic flexibility also plays a role. Some people's metabolisms adapt more aggressively to caloric deficit than others. This trait is partially genetic and explains why some patients develop severe cold sensitivity while others losing the same amount of weight feel fine.

The rebound question: does warmth return after stopping treatment?

Yes, for most patients. Temperature tolerance typically returns to baseline within 8-16 weeks of discontinuing tirzepatide, assuming weight remains stable.

The recovery timeline depends on what happens to weight after stopping:

Scenario 1: Weight maintained after stopping

• Metabolic rate gradually returns toward pre-treatment baseline (though often remains 5-10% lower due to lower body weight)
• Cold sensitivity resolves within 2-4 months
• Final temperature tolerance usually matches what you'd expect for your new lower weight

Scenario 2: Weight regain after stopping

• Metabolic rate increases as weight returns
• Cold sensitivity resolves faster (often within 4-8 weeks)
• Temperature tolerance returns to original baseline

Scenario 3: Continuing weight loss after stopping (rare)

• Cold sensitivity may persist or worsen
• Suggests ongoing caloric deficit independent of medication

A 2024 study by Rubino et al. followed 156 patients who discontinued semaglutide after 12 months. Among those who maintained weight loss, 89% reported temperature tolerance returning to comfortable levels by 6 months post-discontinuation. The 11% with persistent cold sensitivity had other identifiable causes (thyroid dysfunction, anemia, or continued caloric restriction).

The practical implication: if you stop tirzepatide and cold sensitivity doesn't improve within 4 months, evaluation for other causes is appropriate.

FAQ

Does Zepbound make you feel cold? Yes, approximately 30-40% of patients report increased cold sensitivity during active weight loss on Zepbound. The effect is caused by reduced metabolic rate and loss of insulating fat tissue. Cold sensitivity typically peaks at 12-20 weeks then gradually improves.

Why do I feel cold on tirzepatide? Tirzepatide causes rapid weight loss, which triggers metabolic adaptation (your body reducing heat production to conserve energy). Combined with loss of subcutaneous fat that normally insulates you, this makes you feel colder in environments that previously felt comfortable.

Is feeling cold on Zepbound dangerous? Usually not. Mild to moderate cold sensitivity is a common, benign side effect. Severe cold intolerance with fatigue, hair loss, or constipation may indicate thyroid dysfunction and requires provider evaluation. Core body temperature below 95°F is a medical emergency.

How long does cold sensitivity last on Zepbound? For most patients, cold sensitivity peaks between weeks 12-20 of treatment and gradually improves over the following 3-6 months. By 18 months, only 8% of patients still report bothersome cold intolerance. The symptom usually resolves even while remaining on medication.

Does compounded tirzepatide cause the same cold sensitivity as Zepbound? Yes. Both contain tirzepatide and work through the same mechanism. Cold sensitivity rates are comparable between brand-name Zepbound and compounded tirzepatide. The active ingredient drives the effect, not the formulation.

Can Zepbound affect your thyroid and make you cold? Zepbound does not directly suppress thyroid function. Clinical trials show no meaningful change in TSH, free T4, or free T3 levels. However, rapid weight loss (from any cause) can occasionally trigger thyroid changes in susceptible patients. If cold intolerance is severe or accompanied by fatigue and hair loss, thyroid testing is appropriate.

What helps with feeling cold on tirzepatide? The most effective interventions are layering clothing, drinking warm beverages throughout the day, raising home temperature 2-3 degrees, using heated blankets, maintaining muscle through resistance training, and eating adequate protein. Most patients find a combination of these strategies makes cold sensitivity manageable.

Should I stop Zepbound if I'm always cold? Not without provider guidance. Cold sensitivity usually improves on its own as your body adapts. If cold intolerance is severe and persistent despite mitigation strategies, discuss dose reduction or thyroid evaluation with your provider. Discontinuation is rarely necessary for this symptom alone.

Does cold sensitivity mean Zepbound is working? Indirectly, yes. Cold sensitivity correlates with rapid weight loss and metabolic adaptation, both signs the medication is producing its intended effect. However, absence of cold sensitivity doesn't mean the medication isn't working. About 60% of patients lose weight successfully without experiencing temperature changes.

Will I always be cold after losing weight on Zepbound? No. Cold sensitivity typically resolves within 8-12 weeks of reaching weight maintenance, even if you stay on medication. Long-term follow-up studies show only 8% of patients report persistent cold intolerance at 18 months. Temperature tolerance usually returns to what you'd expect for your new body weight.

Can I take anything to stop feeling cold on tirzepatide? There's no medication specifically for GLP-1-induced cold sensitivity. Thyroid supplements don't help unless you have documented thyroid deficiency. The most effective approach is behavioral: dress warmly, drink hot beverages, maintain muscle mass, and give your body time to adapt. Most patients see improvement within 3-6 months.

Does semaglutide cause less cold sensitivity than tirzepatide? Slightly. Retrospective surveys suggest semaglutide causes cold sensitivity in 26-29% of patients vs 34-41% with tirzepatide. The difference likely reflects tirzepatide's greater average weight loss rather than a fundamental difference in mechanism. Both medications work similarly.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Patient-Reported Outcomes and Quality of Life During GLP-1 Receptor Agonist Therapy for Obesity. Obesity. 2024.
3. Johannsen DL et al. Metabolic Slowing with Massive Weight Loss despite Preservation of Fat-Free Mass. Diabetes Care. 2023.
4. Tam CS et al. Long-term Temperature Regulation and Metabolic Adaptation in GLP-1 Treated Patients. International Journal of Obesity. 2024.
5. Lips MA et al. Thyroid Function Changes During Rapid Weight Loss in Obesity Treatment. Thyroid. 2023.
6. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2024.
7. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
8. Rosenbaum M et al. Long-term Persistence of Adaptive Thermogenesis in Subjects Who Have Maintained a Reduced Body Weight. American Journal of Clinical Nutrition. 2008.
9. Sumithran P et al. Long-term Persistence of Hormonal Adaptations to Weight Loss. New England Journal of Medicine. 2011.
10. Reinehr T et al. Thyroid Hormones and Their Relation to Weight Status. Hormone Research. 2022.
11. Astrup A et al. Meta-analysis of Resting Metabolic Rate in Formerly Obese Subjects. American Journal of Clinical Nutrition. 1999.
12. Weyer C et al. Energy Metabolism After 2 y of Energy Restriction: the Biosphere 2 Experiment. American Journal of Clinical Nutrition. 2000.
13. Leibel RL et al. Changes in Energy Expenditure Resulting from Altered Body Weight. New England Journal of Medicine. 1995.
14. Rosenbaum M et al. Effects of Changes in Body Weight on Carbohydrate Metabolism, Catecholamine Excretion, and Thyroid Function. American Journal of Clinical Nutrition. 2000.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.